This study was completed by two teams that worked independently, each composed of a clinician and research scientists, in collaboration with a researcher from Johns Hopkins
In UK practice, code the clinical manifestation first (e.g., R11.0 for nausea), followed by Y42.3 (Insulin and oral hypoglycaemic drugs causing adverse effects in therapeutic use) as the secondary external cause code
What About High-Risk Medications
Similarly, symptoms suggestive of gallbladder disease warrant investigation with liver function tests and abdominal ultrasonography
This knowledge ensures comprehensive patient care, appropriate risk stratification, and timely intervention when complications arise
The two teams came to similar conclusions